You are here

Novartis puts pressure on Roche with cheap copy of Rituxan

Zurich

SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.

Rixathon, from Novartis's Sandoz generics...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes